Genomics-Informed Model Beneficial for Neurodevelopmental Disorders
MONDAY, Dec. 30, 2024 -- For patients with neurodevelopmental disorders (NDDs), a genomics-informed model can provide clinical benefits, directly affecting management, according to a study published online Dec. 18 in Genetics in Medicine.
Aaron D. Besterman, M.D., from the University of California San Diego, and colleagues performed a retrospective study of 316 patients from a genomics-informed multidisciplinary, neuropsychiatric specialty clinic to examine the impact on diagnosis and management of patients with NDDs.
The researchers found that 41.8 percent of the 246 patients who underwent genetic testing had a pathogenic or likely pathogenic variant. Sixty-two different genetic diagnoses were identified: 12 diagnoses were shared by two or more patients and 50 diagnoses were in only single patients. In all patients with a pathogenic or likely pathogenic variant, genetic diagnoses resulted in direct changes to clinical management, including cascade testing, family counseling, medication changes, clinical trial referral, medical surveillance, and specialty referrals (30.6, 22.2, 13.9, 2.8, 30.6, and 69.4 percent, respectively).
"Genomics-informed education and care for NDDs should be inclusive and adaptable because the number of identifiable neurogenetic conditions continues to grow and precision treatments for many neurogenetic disorders are under development," the authors write.
One author disclosed ties to Mirum Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Features of Immunesenescence Present in Early Stages of Rheumatoid Arthritis
THURSDAY, Sept. 11, 2025 -- Some features of immunesenescence are present in the very early stages of rheumatoid arthritis (RA), according to a study published online Sept. 3 in...
Urine Biomarker Panel Sensitive, Specific for Prostate Cancer Diagnosis
THURSDAY, Sept. 11, 2025 -- A urine-based biomarker panel has high accuracy for diagnosing prostate cancer (PCa), according to a study published in the September issue of...
Hospitals Vary in Their Definition of Blood Culture Contamination
THURSDAY, Sept. 11, 2025 -- U.S. hospitals vary in how they define blood culture contamination (BCC), according to a study published online July 11 in the Journal of Clinical...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.